Kyntra Bio Inc

Financials

Activos totales 826.84 M773.82 M610.09 M423.53 M214.53 M119.59 M Total de pasivos 385.39 M544.71 M611.57 M585.73 M398.16 M115.12 M Capital total 441.45 M229.11 M-1.48 M-183.68 M-205.12 M-17 M Total de pasivos y patrimonio neto 826.84 M773.82 M610.09 M423.53 M214.53 M119.59 M Deuda total ———71.97 M73.13 M0 Deuda neta ———-83.04 M22.61 M-88.98 M

Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate. On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB.